title: The HIV/HCV-coinfected patient and new treatment options.
abstract: Hepatitis C (HCV) treatment is on the cusp of change with the approval of the first direct-acting antivirals: telaprevir and boceprevir. Drug-drug interactions with HIV antiretrovirals, increased toxicity, and rapid selection of HCV-resistant mutants are among the treatment complexities expected in this difficult-to-treat population. Until the current standard of care changes, focus should be on strategies to optimize management of HIV/HCV-coinfected patients with currently available options. This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options.
authors.affiliation: Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA.
authors.forename: Marie-Louise C
authors.initials: ML
authors.lastname: Vachon
authors.forename: Douglas T
authors.initials: DT
authors.lastname: Dieterich
mesh_terms: D018791:CD4 Lymphocyte Count; D060085:Coinfection / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D006526:Hepatitis C / Q000188:drug therapy* / Q000401:mortality / Q000821:virology; D006801:Humans; D007333:Insulin Resistance; D007372:Interferons; D007378:Interleukins / Q000235:genetics; D014808:Vitamin D Deficiency / Q000276:immunology; D000095022:Interferon Lambda
chemical_list: D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda